NOVO NORDISK A/S
Commented by Stefan Feulner on March 11th, 2024 | 06:30 CET
Novo Nordisk, Defence Therapeutics, Bayer - Rally after the breakout?
Biotechnology has been revived after a disappointing stock market year in 2023. In addition to the interest rate cut fantasy, which should benefit the capital-intensive and innovative sector in particular, the current wave of acquisitions should lead to further price rises. Although the broad Nasdaq Biotech Index has only risen by 3% since the beginning of the year, it is currently facing key resistance levels. If these are broken through, the momentum northwards could accelerate.
Read
Commented by Stefan Feulner on February 7th, 2024 | 07:00 CET
Novo Nordisk, Cardiol Therapeutics, Morphosys - Biotechs on a high
After a disappointing stock market year 2023, there is a gold-rush mood in the biotechnology and pharmaceutical sectors. Big names such as Eli Lilly, Vertex, Amgen and Novartis are going from high to high and possess enormous momentum. Acquisitions have also increased dramatically in recent months. The takeover prices are usually significantly higher than the current share prices of the listed companies. This wave will likely increase further due to the pressure that pharmaceutical giants are feeling as licenses expire.
Read
Commented by Stefan Feulner on November 21st, 2023 | 07:00 CET
Novo Nordisk, Defence Therapeutics, Morphosys - The biotechs are coming
The capital-intensive biotech sector was hit particularly hard when the US Federal Reserve began the massive interest rate hikes from zero to 5.5% in the first quarter of 2022. Since then, the broad-based Nasdaq Biotech Index has lost around 20% of its value. With the end of the strict monetary policy, this sector is now likely to experience a revival on the stock market. There is significant catching-up potential, especially among second-tier stocks.
Read
Commented by Stefan Feulner on October 16th, 2023 | 06:50 CEST
Lots of activity in the biotech sector - Novo Nordisk, Defence Therapeutics, Morphosys
Despite the rather gloomy economic outlook on the one hand and high interest rates on the other, there is significant movement in the capital-intensive biotechnology sector. After Amgen successfully concluded the acquisition of Horizon Therapeutics for USD 116.50 per share or a total volume of around USD 27.8 billion, further investments by Big Pharma in innovative and promising technologies will likely follow soon.
Read